About US
Contact us
-
November’s top stories: Actavis buys Allergan, antibiotics misunderstood in UKActavis signs agreement to buy Botox-maker Allergan for $66bn Ireland-based pharmaceutical company Actavis signed an agreement to acquire US-based Botox-maker Allergan for $66bn or $219 per share.2014/12/9
-
KKR agrees to buy significant minority stake in Arbor PharmaceuticalsNew York-based private equity firm KKR has agreed to buy a significant minority stake in specialty drugmaker Arbor Pharmaceuticals, in a bid to help drive continued growth. Financial terms of the tra2014/12/9
-
Merck plans to buy Cubist Pharmaceuticals for $8bnUS-based drugmaker Merck is reportedly planning to buy antibiotics maker Cubist Pharmaceuticals, in a deal valued at more than $8bn. Merck intends to pay $100 per share for Cubist, bringing the value2014/12/9
-
Scientists at Oxford University begin first booster Ebola vaccine trialsScientists at Oxford University have started first booster Ebola vaccine trials to test its safety and evaluate its potential to further increase the immune responses seen in healthy volunteers. The2014/12/8
-
GSK reveals plans to cut sales and research jobs in USGlaxoSmithKline (GSK) has reportedly revealed plans to cut 'several hundred' sales and research jobs in the US. The cuts are part of its global restructuring strategy and cost-saving programme. In a2014/12/8
-
Nanotech takes on antimicrobial resistanceThere are few threats to global health more serious than antimicrobial resistance (AMR). Given that antibiotics represent one of the core pillars of modern medicine, at present there is no easy answer2014/12/8
-
MRIGlobal awarded $3 million contract to provide HPV vaccineMRIGlobal today announced that it has been awarded a $3 million contract amendment from the National Cancer Institute's PREVENT Cancer Program to provide a vaccine for the Human Papillomavirus or HPV,2014/12/5
-
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tabletsMylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (2014/12/5
-
Amgen’s Blincyto approved to treat Ph- relapsed or refractory B-cell precursor ALLAmgen has received approval from US Food and Drug Administration (FDA) for its Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precu2014/12/5
-
Roquette Pharma - Global Supplier of Pharmaceutical Excipients and ActivesRoquette is a long-established supplier of raw materials, excipients and actives to the pharmaceutical and cosmetic industries, which also benefit from its valuable services. Oral dosage forms are st2014/12/3